Curatis Holding AGXSWX:CURN +3.51%33 Gross Margin % is 27.89% as of Dec. 2025, which is 13% above its 10-year median of 24.66. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 7 warning signs investors should review. Among 937 Drug Manufacturers companies, Curatis Holding AG ranks worse than 85.49% on this metric.
The historical rank and industry rank for Curatis Holding AG's Gross Margin % or its related term are showing as below:
XSWX:CURN'
s Gross Margin % Range Over the Past 10 Years
Min: 23 Med: 24.66 Max: 26.32
Current: 26.32
During the past 5 years, the highestGross Margin % of Curatis Holding AG was 26.32%. The lowest was 23.00%. And the median was 24.66%.
XSWX:CURN's Gross Margin % is ranked worse than 85.49% of 937
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs XSWX:CURN: 26.32
Curatis Holding AG had a gross margin of 27.89% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Curatis Holding AG was 0.00% per year.
Curatis Holding AG (XSWX:CURN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Curatis Holding AG had a gross margin of 27.89% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Curatis Holding AG Gross Margin % Related Terms
Curatis Holding AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CURN vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Curatis Holding AG (XSWX:CURN) has a Gross Margin % of 27.89% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Curatis Holding AG and its competitors. This is 13% above median its historical median of 24.66. Over the past decade, Curatis Holding AG's Gross Margin % has ranged from 23.00 to 26.32. According to the industry distribution chart, Curatis Holding AG ranks #801 out of 937 companies in the Drug Manufacturers industry, placing it in the top 85.5%.
Is Curatis Holding AG's Gross Margin % too high?
Curatis Holding AG's current Gross Margin % of 27.89% is 13% above median its 10-year median of 24.66. Over the past 10 years, this metric has ranged from a low of 23.00 to a high of 26.32. The Drug Manufacturers industry median Gross Margin % is 48.46. Curatis Holding AG's value of 27.89% is 42.4% below this industry median. Based on the distribution chart, Curatis Holding AG ranks #801 out of 937 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #801 out of 937 companies for Gross Margin %. This places Curatis Holding AG in the lower half of its industry. The industry median Gross Margin % is 48.46. Curatis Holding AG's value of 27.89% is 42.4% below this benchmark. Historically, Curatis Holding AG's own Gross Margin % has ranged from 23.00 to 26.32 over the past decade. While the company's 10-year median is 24.66 vs. the industry median of 48.46, Curatis Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curatis Holding AG's current Gross Margin % of 27.89% is 42.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Curatis Holding AG and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current Gross Margin % is 27.89%, which is 13% above median its own 10-year median of 24.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current Gross Margin % of 27.89%. The current Gross Margin % is 27.89%, which is 13% above median its 10-year median of 24.66 and 42.4% below the Drug Manufacturers industry median of 48.46. Curatis Holding AG's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current Gross Margin % is 27.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score
Get the complete analysis for XSWX:CURN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
